A number of news articles and reports on elder financial abuse do a good job of highlighting the growing problem of older adults being targeted for financial theft and fraud. This study by MetLife lists the types of financial predation towards seniors that can and do happen. What tends to be missing from these studies… Read More »
Routine health screenings are now common for a variety of conditions like hypertension, diabetes, and glaucoma. Many health insurance plans, including Medicare, provide no cost or low cost health screenings to their members. The main intent behind these preventive health screenings, or wellness screenings, is to provide an early warning system for both consumers and… Read More »
A new survey conducted by the Harvard School of Public Health and Alzheimer Europe points to a strong consumer desire for “predictive testing” – the promise of a medical screening test that can gauge the likelihood of a person declining into Alzheimer’s Disease (AD) as they age. Over two thirds of respondents said that they… Read More »
In April the National Institute on Aging (NIA) and Alzheimer’s Association released revised criteria and guidelines for diagnosing Alzheimer’s Disease (AD). Spread over several documents, the revisions are written in the usual impenetrable language of medical research journals – which makes sense, since the target audience is the medical research professional community. Here at MyBrainTest… Read More »
A recent study published in Neurology points to some interesting results with measuring protein levels in cerebrospinal fluid (CSF). The research effort looked at levels of amyloid precursor protein (APPB) in patients with mild cognitive impairment (MCI), and found that the patients with high APPB levels at the beginning of the study period had a… Read More »
Yesterday the National Institute on Aging and Alzheimer’s Association released much needed and long overdue updates for diagnosing Alzheimer’s Disease (AD). Chief among the revised guidelines are three distinct disease stages: 1- Preclinical AD: no symptoms, but some changes in brain biomarkers. 2- Mild Cognitive Impairment (MCI) due to AD: measurable memory impairment, but little… Read More »